These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19788018)

  • 1. Baseline characteristics of patients enrolled in EXCELS: a cohort study.
    Long AA; Fish JE; Rahmaoui A; Miller MK; Bradley MS; Taki HN; Demeo AN; Tilles SA; Szefler SJ
    Ann Allergy Asthma Immunol; 2009 Sep; 103(3):212-9. PubMed ID: 19788018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
    Long A; Rahmaoui A; Rothman KJ; Guinan E; Eisner M; Bradley MS; Iribarren C; Chen H; Carrigan G; Rosén K; Szefler SJ
    J Allergy Clin Immunol; 2014 Sep; 134(3):560-567.e4. PubMed ID: 24679845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
    Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
    Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
    Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
    Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.
    Eisner MD; Zazzali JL; Miller MK; Bradley MS; Schatz M
    J Asthma; 2012 Aug; 49(6):642-8. PubMed ID: 22793527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pretreatment specific IgE and the response to omalizumab therapy.
    Wahn U; Martin C; Freeman P; Blogg M; Jimenez P
    Allergy; 2009 Dec; 64(12):1780-7. PubMed ID: 19627273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab: a novel therapy for allergic asthma.
    Davis LA
    Ann Pharmacother; 2004; 38(7-8):1236-42. PubMed ID: 15187202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma.
    Dolan CM; Fraher KE; Bleecker ER; Borish L; Chipps B; Hayden ML; Weiss S; Zheng B; Johnson C; Wenzel S;
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):32-9. PubMed ID: 14756462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
    Slavin RG; Ferioli C; Tannenbaum SJ; Martin C; Blogg M; Lowe PJ
    J Allergy Clin Immunol; 2009 Jan; 123(1):107-113.e3. PubMed ID: 19130931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.
    Oba Y; Salzman GA
    J Allergy Clin Immunol; 2004 Aug; 114(2):265-9. PubMed ID: 15316501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.